Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$21.36
+0.7%
$22.69
$18.70
$29.55
$1.01B1.82409,253 shs594,780 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.10
$4.65
$13.13
$1.10B1.471.14 million shs19.38 million shs
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$15.49
+1.2%
$16.94
$9.70
$25.00
$1.03B1.63187,715 shs193,219 shs
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
$27.82
+2.0%
$30.30
$25.86
$39.08
$242.46M1.3627,365 shs26,858 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
+0.66%-4.17%-1.93%-17.27%+1.71%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.65%+128.31%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
+1.24%+1.04%-8.29%-2.27%+44.23%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
+1.98%-2.96%-8.46%-10.83%-0.54%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.321 of 5 stars
3.51.00.00.02.32.50.6
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
1.205 of 5 stars
0.01.00.04.21.34.20.0
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
1.8486 of 5 stars
3.51.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$31.1745.91% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
0.00
N/AN/AN/A
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
3.00
Buy$49.5077.93% Upside

Current Analyst Ratings Breakdown

Latest SMTI, BLFS, PLSE, and FNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$51.00 ➝ $53.00
5/13/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/26/2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$46.00 ➝ $46.00
3/26/2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $51.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$82.25M12.34$0.12 per share173.21$7.52 per share2.84
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$700K1,488.59N/AN/A$1.87 per share8.28
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
$86.67M2.85N/AN/A$4.45 per share6.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$20.18M-$0.29N/AN/AN/A-11.81%-0.66%-0.58%8/14/2025 (Estimated)
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
-$53.58MN/A0.00N/AN/A-68.44%-58.17%8/14/2025 (Estimated)
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$9.66M-$1.34N/AN/AN/A-12.48%-29.22%-13.20%8/11/2025 (Estimated)

Latest SMTI, BLFS, PLSE, and FNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$0.31-$0.41-$0.10-$0.41$23.48 million$23.43 million
5/8/2025Q1 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million
5/8/2025Q1 2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/A-$0.25N/A-$0.25N/AN/A
3/25/2025Q4 2024
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$0.19-$0.18+$0.01-$0.18$22.75 million$26.31 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.01
4.73
3.74
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/A
15.58
15.58
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
1.18
2.77
2.54

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
76.95%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
8.10%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
71.50%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
42.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.50 million46.46 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
14067.27 million19.17 millionOptionable
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
608.89 million5.10 millionNot Optionable

Recent News About These Companies

Sanara MedTech to Present at Investor Showcase

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$21.36 +0.14 (+0.66%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$21.76 +0.40 (+1.85%)
As of 06/23/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Pulse Biosciences stock logo

Pulse Biosciences NASDAQ:PLSE

$15.49 +0.19 (+1.24%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$15.49 0.00 (0.00%)
As of 06/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Sanara MedTech stock logo

Sanara MedTech NASDAQ:SMTI

$27.82 +0.54 (+1.98%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$27.86 +0.04 (+0.14%)
As of 06/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.